{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:14:45Z","timestamp":1784139285564,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urology"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.urology.2007.09.050","type":"journal-article","created":{"date-parts":[[2008,3,6]],"date-time":"2008-03-06T18:27:11Z","timestamp":1204828031000},"page":"297-301","source":"Crossref","is-referenced-by-count":84,"title":["Impact of Previous Bacille Calmette-Gu\u00e9rin Failure Pattern on Subsequent Response to Bacille Calmette-Gu\u00e9rin Plus Interferon Intravesical Therapy"],"prefix":"10.1016","volume":"71","author":[{"given":"Brian L.","family":"Gallagher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi N.","family":"Joudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Maym\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1016\/j.urology.2007.09.050_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000052386","article-title":"Treatment of superficial bladder tumors: achievements and needs","volume":"37","author":"Kurth","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0022-5347(17)45604-7","article-title":"Long-term effect of intravesical bacillus Calmette-Gu\u00e9rin on flat carcinoma in situ of the bladder","volume":"135","author":"Herr","year":"1986","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib3","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0022-5347(17)36197-9","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule","volume":"149","author":"Melekos","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Gu\u00e9rin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance Bacillus Calmette-Gu\u00e9rin for Ta T1 bladder tumours is not associated with increased toxicity: results from a European Organization for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib6","first-page":"39","article-title":"Intravesical therapy: does it affect the natural history of superficial bladder cancer?","volume":"10","author":"Lamm","year":"1992","journal-title":"Semin Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib7","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary interleukin-8 and -18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Gu\u00e9rin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00262-003-0384-9","article-title":"Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Gu\u00e9rin immunotherapy for carcinoma in situ of the bladder","volume":"52","author":"Watanabe","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urology.2007.09.050_bib9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ijc.11352","article-title":"Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Gu\u00e9rin response of superficial bladder cancer during induction course and maintenance therapy","volume":"107","author":"Saint","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urology.2007.09.050_bib10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1046\/j.1464-410x.1999.00208.x","article-title":"Elevated urinary fibronectin levels after transurethral resection of bladder tumor: a possible role in patients failing therapy with bacillus Calmette-Gu\u00e9rin","volume":"84","author":"Laufer","year":"1999","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2007.09.050_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.eururo.2006.06.006","article-title":"HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumors","volume":"51","author":"Lebret","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-006-0112-0","article-title":"Treatment options for BCG failures","volume":"24","author":"O\u2019Donnell","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2007.09.050_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1464-410X.1998.00720.x","article-title":"Bacille Calmette-Gu\u00e9rin in superficial transitional cell carcinoma","volume":"82","author":"Mungan","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib15","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","article-title":"IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Gu\u00e9rin immunotherapy","volume":"162","author":"Luo","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.urology.2007.09.050_bib16","first-page":"1790","article-title":"Management of bacillus Calmette-Gu\u00e9rin (BCG) refractory superficial bladder cancer: results with intravesical BCG and interferon combination therapy","volume":"10","author":"Punnen","year":"2003","journal-title":"Can J Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1078-1439(03)00012-7","article-title":"Bacillus Calmette-Gu\u00e9rin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity","volume":"21","author":"Lam","year":"2003","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2007.09.050_bib18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urology.2007.09.050_bib19","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Gu\u00e9rin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0090-4295(97)00067-8","article-title":"Additional bacillus Calmette-Gu\u00e9rin therapy for recurrent transitional cell carcinoma after initial complete response","volume":"49","author":"Bui","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.urology.2007.09.050_bib21","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib22","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0022-5347(17)40067-X","article-title":"The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Gu\u00e9rin","volume":"143","author":"Bretton","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib23","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0302-2838(02)00491-8","article-title":"Beware the BCG failures: a review of one institution\u2019s results","volume":"42","author":"Lockyer","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2007.09.050_bib24","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Gu\u00e9rin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429507021875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429507021875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T17:47:04Z","timestamp":1684259224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429507021875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0090429507021875"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2007.09.050","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}